Overview and Scope
Genomics in cancer care refers to the examination of all variations in DNA sequence and gene expression between tumor cells and healthy host cells to recognize the patients’ genetic backgrounds to provide better cancer treatment. Genomics in cancer care is used to detect cancer-causing mutations, enhance tumor-specific diagnostic techniques and treatment plans, enable precision medicine research and drug development, and allow the development of targeted therapies to offer personalized medicines to patients suffering from various types of cancers.
Sizing and Forecast
The genomics in cancer care market size has grown rapidly in recent years. It will grow from $15.08 billion in 2023 to $17.79 billion in 2024 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to early research and development, development of companion diagnostics, ethical and legal frameworks, data standardization and interpretation, initial market penetration..
The genomics in cancer care market size is expected to see rapid growth in the next few years. It will grow to $33.28 billion in 2028 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to increasing prevalence of cancer, advancements in data analytics, market expansion in emerging economies, genomic data privacy and security, improving healthcare infrastructure.. Major trends in the forecast period include technological advancments, personalized medicine, reduced costs of genomic sequencing, regulatory support and guidelines, patient awareness and demand..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/genomics-in-cancer-care-global-market-report
Segmentation & Regional Insights
The genomics in cancer care market covered in this report is segmented –
1) By Product Type: Instruments, Consumables, Services
2) By Technology: PCR (Polymerase Chain Reaction), MicroArrays, Genome Sequencing, Other Technologies
3) By Application: Diagnostics, Personalized Medicine, Drug Discovery And Development, Research
4) By End-user: Hospitals, Government Institutes, Research Facilities
North America was the largest region in the genomics in cancer care market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomics in cancer care market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8159&type=smp
Major Driver Impacting Market Growth
Growing demand for cancer diagnostics is expected to propel genomics in the cancer care market. Cancer diagnostics refers to identifying the right tumor kind, location, extent, and stage by tests and procedures confirming the disease’s presence. Genomics in cancer care helps in determining a suitable treatment plan for cancer patients by recognizing their genetic backgrounds. For instance, in January 2021, according to the data published in ACS Journals, a US-based cancer journal for clinicians, a total of 1.8 million new cancer cases were diagnosed in the United States. Furthermore, in September 2020, the National Cancer Institute, a US-based national health institute, reported that the annual incidence of new cancer cases was 442.4 per 100,000 men and women. Therefore, the growing demand for cancer diagnostics is expected to drive genomics in the cancer care market.
Key Industry Players
Major companies operating in the genomics in cancer care market report are Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., QIAGEN N.V., Bio-Rad Laboratories Inc., Danaher Corporation, Vyant Bio Inc., Pacific Biosciences of California Inc., Roche Holding AG, Quest Diagnostics Incorporated, DiaSorin S.p.A., BGI Group, Myriad Genetics Inc., Healthcare Global Enterprises Ltd., NeoGenomics Laboratories, Foundation Medicine Inc., Intermountain Healthcare, Laboratory Corporation of America Holdings, Flatiron Health Inc., Personal Genome Diagnostics Inc., Natera Inc., GRAIL Inc., Freenome Holdings Inc., Genomic Health Inc., Caris Life Sciences Inc., Tempus Labs Inc., OncoDNA S.A., Cancer Genetics Inc., Biocept Inc., GenomOncology Corp., OncoCyte Corporation, PathAI Inc., Enzyme Corporation, Karius Inc., N-of-One Inc., Oncora Medical Inc., Paradigm Diagnostics Inc., PierianDx Inc., Predicine Inc., Resolution Bioscience Inc., Strata Oncology Inc.
The genomics in cancer care market report table of contents includes:
1. Executive Summary
2. Genomics In Cancer Care Market Characteristics
3. Genomics In Cancer Care Market Trends And Strategies
4. Genomics In Cancer Care Market – Macro Economic Scenario
5. Global Genomics In Cancer Care Market Size and Growth
.
.
.
31. Global Genomics In Cancer Care Market Competitive Benchmarking
32. Global Genomics In Cancer Care Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Genomics In Cancer Care Market
34. Genomics In Cancer Care Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
